Work

OX40 agonist immunotherapy expands tumor reactive CD8 T cells with a unique T cell receptor repertoire and synergizes with PDL-1 blockade to promote tumor regression

Year: 2014

Type: article

Abstract: Meeting abstracts Previously, the field of tumor immunology has relied on T cell receptor (TCR) transgenic mice and model tumor antigens to study the T cell:tumor cell interaction. However, these models have limitations. Namely, they do not reflect the natural affinity, repertoire, or precursor

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-2-s3-o18

Authors: Amy Moran, Fanny Polesso, Andrew Weinberg

Institution: Providence Portland Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490